LMR Partners’s Intellia Therapeutics NTLA Stock Holding History

LMR Partners’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-71,100	Closed	-$829K	–	1561
2024 Q4	$829K	Hold	71,100	–	–	0.01%	758
2024 Q3	$1.46M	Buy	71,100 +18,533	+35%	+$427K	0.01%	675
2024 Q2	$1.18M	Buy	52,567 +22,609	+75%	+$538K	0.01%	639
2024 Q1	$824K	Buy	29,958 +2,468	+9%	+$68.6K	0.01%	700
2023 Q4	$838K	Sell	27,490 -2,800	-9%	-$80.5K	0.01%	599
2023 Q3	$958K	Buy	30,290 +11,600	+62%	+$450K	0.01%	495
2023 Q2	$762K	Buy	+18,690	New	+$758K	0.01%	453
2023 Q1	–	Sell	-13,192	Closed	-$460K	–	1131
2022 Q4	$460K	Sell	13,192 -10,816	-45%	-$514K	0.01%	888
2022 Q3	$1.34M	Buy	24,008 +9,856	+70%	+$611K	0.02%	644
2022 Q2	$733K	Sell	14,152 -3,497	-20%	-$178K	0.01%	836
2022 Q1	$1.28M	Buy	+17,649	New	+$1.5M	0.01%	720

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

LMR Partners's NTLA Position: Q1 2025 in Review

LMR Partners sold out of Intellia Therapeutics (NTLA) in Q1 2025, closing a stake of 71,100 shares — an estimated $829K sold.

LMR Partners first reported a position in NTLA in Q1 2022 and held it in 11 quarters. The position peaked at $1.46M in Q3 2024. 294 funds tracked by Wall St. Rank hold NTLA as of Q1 2025.

LMR Partners reported no remaining Intellia Therapeutics position as of Q1 2025 after selling out during the quarter.
LMR Partners sold 71,100 Intellia Therapeutics shares in Q1 2025, an estimated $829K.
LMR Partners first reported a position in Intellia Therapeutics in Q1 2022 and held it in 11 quarters.
LMR Partners's Intellia Therapeutics position peaked at $1.46M in Q3 2024.
294 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2025.

Based on LMR Partners's 13F filing for Q1 2025, filed 15 May 2025.